gretel
02 May 2018
News: new product range [link] new blue G:BOX multi-application imaging range from SyngeneMay 1st, 2018Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to introduce its new look G:BOX range of upgradeable multi-application imaging systems. Designed with a sleek new darkroom, each of these systems includes top quality imaging features, making it easy for scientists to accurately quantify DNA and protein on all types of gels and blots.The new look range (G:BOX Chemi XRQ, G:BOX Chemi XX6 and XX9) combine a unique motorized stage (XX6 and XX9) and super-cooled camera inside a streamlined new light-tight darkroom. These features ensure G:BOX systems produce true to life, low-noise optical images rather than poor quality, digitally enhanced ones. With a G:BOX system, scientists can resolve close chemi and fluorescent bands and know they’re real, which means these systems are ideal for robust quantification of as little as femtogram quantities of DNA and proteins on multiple gel and blot types.With the option to add Red, Green, Blue and Infra Red Hi-Intensity ( HI-LED) lights that are up to 200 times brighter than standard LEDs, the new G:BOX range offers fast exposure times and produces brilliant multiplex fluorescence images. With a G:BOX Chemi system, users can detect up to five fluorescent channels sequentially (from UV to IR) on Western blots. For higher performance and resolution, researchers can use a G:BOX Chemi XX6 or XX9 for imaging close bands or spots even on complex 2D gels.At the heart of the new look G:BOX range is the unique, application driven, GeneSys software which walks users through hassle-free imaging set up. With minimal hands on time, scientists can easily design customised workflows to rapidly and reproducibly produce publication quality images of chemi, multiplex fluorescence blots, DNA and stain-free protein gels. The software includes QuickQuant, for band quantification, saving scientists time, by allowing them to quantify images of protein and DNA bands while capturing their blot or gel images at their G:BOX system.To complete the package, the new G:BOX systems come with Syngene’s exclusive three-year service and support warranty, unlimited copies of GeneTools image analysis software and free software upgrades, ensuring scientists will always have access to the latest application capabilities without any hidden extra costs.To find out more about the exciting new look G:BOX range, please click this link:[link] researchers want to get optimum imaging from simple gels right through to multiplex fluorescence applications, with minimal hands on time” says Dr Martin Biggs, Sales Manager at Syngene. “Our new systems perform perfectly to fit these needs, so scientists wanting hassle free imaging and results they can trust, should look at Syngene’s new G:BOX range today.”
gretel
02 May 2018
Re: Doing well Hope so 
))
IOMINVESTCOM
02 May 2018
Doing well A few decent buys going thru this am close to 42p and now at new highs for a while.Wondering whether SCSW this weekend will give it more thumbs up and add some more fuel to the fire and will see further strength.atb
gretel
01 May 2018
Great coverage by the Private Punter Excellent new article on SDI by the Private Punter as usual:[link] great extracts, particularly re Sentek:"The division, which is the UK's largest independent manufacturer of electrochemical sensors for water based applications, delivered a stronger second half performance than was previously expected which in turn was assisted by increased demand from two large OEM customers. Additionally, Sentek has taken up the opportunity to facilitate continued growth with an added extra facility to double capacity that had previously been earmarked being adjacent to its existing HQ."And acquisitions:"Creedon, while content with the progress, anticipates further additions to the group with a sizeable banking facility now in place to support that goal should they need it. There is he says, currently a strong pipeline of further potential acquisitions that fit the bill for SDI and holders or watchers of the shares will no doubt hear more on that front in due course."And ProReveal:"sales have been made overseas in both Norway and Romania which sees the total since launch of the device now standing at 76. The vast US market also remains on the agenda for future adoption and growth, although it would appear that the UK, given that looming deadline date remains the primary focus for now.""Creedon is certainly not one to raise hopes on the device, but says he will be interested to see exactly what happens come July, as this is the date that has been set by the department of health (DoH) regarding healthcare providers engaged in the management and decontamination of surgical instruments implementing their guidance on protein levels being measured directly on the surface of the instrument."
gretel
30 Apr 2018
Re: Trading Update Great to see Friday's "ahead of expectations" trading update. I particularly like the confident outlook comment, which promises well for the coming year:"SDI is benefitting from its acquisitions as well as from the improvements management continue to make across the whole Group. We look forward to further growth in the new financial year."Finncap seem to be playing things down prior to the prelims, so may well upgrade the target price etc further after the actual results.Hopefully there'll be another earnings-enhancing acquisition along fairly soon too.I was at Mello on Thursday/Friday, and Paul Scott featured SDI quite heavily as one to watch in his Friday morning slot, so this may attract a few newbies into the stock.
claude reins
27 Apr 2018
Re: RNS: German fund take 5.2% stake All good news Gretel. This and the positive trading update.
IOMINVESTCOM
27 Apr 2018
Trading Update Trading UpdateScientific Digital Imaging plc, the AIM quoted group focused on the design and manufacture of scientific and technology products for use by the life science, healthcare, astronomy, consumer manufacturing and art conservation markets, is pleased to announce an update on trading for the year ending 30 April 2018.The Group now expects full year revenues, adjusted* and reported profit before tax to be moderately ahead of previous expectations. In addition, adjusted* and reported profit after tax is expected to benefit from a reduced Group tax charge which includes increased R&D tax credits accrued for both FY18 and FY17.The Group expects to report significant revenue growth against FY17, reflecting both organic growth, and the acquisition of Astles Control Systems in H2 FY17, Applied Thermal Control in H1 FY18, and a contribution from the smaller Quantum Scientific Imaging acquisition in H2 FY18. Sentek's single-use electrodes and Atik Camera's new products for astronomy and life science applications have been key to delivering the organic sales growth.Group gross margin is expected to be ahead of FY17 mainly due to the inclusion of a one-off retrospective licencing payment for the sale of Auto-Montage imaging software in Synoptics' H1 FY18 sales, as previously disclosed in the interim results.Ken Ford, Chairman of SDI, commented:"SDI is benefitting from its acquisitions as well as from the improvements management continue to make across the whole Group. We look forward to further growth in the new financial year."The final results for the year ended 30 April 2018 will be released in July 2018.* before amortisation of acquired intangibles, share based payments and acquisition and reorganisation costs
gretel
24 Apr 2018
RNS: German fund take 5.2% stake Universal-Investment-Luxembourg S.A take a 5.2% stake in SDI with 4.66m shares:[link] they are:[link] S.A. is a wholly owned subsidiary of Universal-Investment-Gesellschaft mbH, Frankfurt am Main. With more than € 130 billion in funds under management (December 2011), more than 1000 special investor and mutual fund mandates and around 400 employees at both locations, the group is one of Germany’s biggest and most successful investment companies."
gretel
05 Apr 2018
Re: Another win for ProReveal It's the increasing recurring revenues from the sale of each ProReveal machine which are really appealingSDI have also posted a nice testimonial as regards the latest ProReveal sale:[link] 3rd April, 2018ProReveal Testimonial - Nottingham University Hospitals NHS Trust“We purchased a ProReveal in May 2017 because we needed a user-friendly in-situ protein detection method to comply with the new Department of Health regulations on testing reprocessed surgical instruments. Since using the ProReveal, we have identified areas for improvement in our processes and instruments that we can’t clean. This has helped us to get our decontamination process to routinely clean to less than 5 micrograms of residual protein per instrument side, which we’re very pleased with.”“The ProReveal is great technology and is easy to use as it guides us step by step. In fact, we like it so much that we often show the ProReveal to visitors to our department. The best thing about having a ProReveal is that we don’t have to rely on subjective judgement calls if there are process issues because we have traceable, quantitative data to assure us that the surgical instruments we’re sending back to be used on patients are safe and fit for purpose.”Alison Gee, Sterile Services and Stores Manager, Nottingham University Hospitals NHS Trust, Nottingham, UK."
gretel
04 Apr 2018
Another win for ProReveal Excellent news...(claude, you must be happier now! Just be patient with this one, there's potentially a long way to go imho):[link] Tuesday 3rd April, 2018Nottingham University Hospitals Trust NHS Trust adopts ProReveal systemCambridge, UK: Synoptics Health, a manufacturer of innovative digital imaging systems for healthcare applications, today announced that its ProReveal test to accurately detect proteins on surgical instruments is being used at Nottingham University Hospitals NHS Trust, one of the UK’s largest NHS run Sterile Services Departments (SSDs). ProReveal is being used to check the washer-disinfection process maintains its excellent cleaning standards and is helping to prevent patients at this hospital trust from accidentally contracting infections such as vCJD (Creutzfeldt Jakob Disease) from protein contaminated surgical instruments.The SSD at Nottingham University Hospitals NHS Trust is one of the first in the UK to adopt the highly sensitive ProReveal in-situ fluorescence test to quantify how much protein remains on surgical instruments after they have been decontaminated. SSD personnel at the hospital test how well their washer-disinfection equipment has performed using the ProReveal (the only commercial in-situ protein detection test currently available that complies with new UK Department of Health [DoH] guidelines) to directly measure proteins on instrument surfaces which cannot be detected by eye or with a swab test. This is making checking the efficacy of the decontamination process more accurate.Alison Gee, Sterile Services and Stores Manager at Nottingham University Hospitals NHS Trust explained: “The Department of Health guidance has changed and SSDs are expected to move to in situ testing for residual protein on surgical instruments. This is particularly important for instruments which are likely to have been in contact with tissue potentially harbouring prions that could cause infections such as vCJD. This change in regulations has actually allowed us to more easily access the funding to purchase and install a ProReveal in our department.”Alison continued: “Since using ProReveal in the past year, we have had very good results, but we have found that a few instruments sometimes have slightly more than the target of five micrograms of protein on them, due to factors such as positioning in the washer-disinfector. We have also identified one type of instrument that we cannot clean adequately for re-use which is therefore being replaced. Neither of these problems were identified using swab testing. This has prompted us to re-train our staff on how to load our machines correctly and to contact the instrument manufacturer to discuss decontamination processes for their products. Additionally, when we had an issue with our water softener, we used the ProReveal and it assured us that the water quality had not affected the decontamination process and the surgical instruments were safe to use. This meant we didn’t have to do routine manual pre-cleaning on everything, so we avoided having an operational backlog and cancelling patients’ surgery. We are very pleased to have the ProReveal as it is assuring us that the surgical instruments we are returning to be used on patients are safe and fit for purpose.”Guy Fiddian, of Synoptics Health concluded: “We’re delighted that one of the UK’s largest NHS Sterile Services Departments is implementing the ProReveal as part of its modern approach to quality control of its decontamination process. Nottingham is one of the first NHS trusts in England to install a ProReveal and its SSD staff’s willingness to embrace using in-situ testing of reprocessed surgical instruments is a great testament to the fact that this excellent trust’s ethos of 'working together to be the best for patients' is at the heart of its care.”
claude reins
13 Feb 2018
Big sell off this morning Any thoughts? Looking at the institutional shareholdings, could be a sell down of one of the bigger ones or a complete sell off by one of the medium ones at around 3m shares. Anything to add, Gretel especially, since I know you watch these carefully?
gretel
07 Feb 2018
ProReveal progressing nicely Peskett Solutions devoted their entire stand at a recent exhibition to ProReveal (I seem to remember ProReveal is now in 15 NHS trusts compared to the 10 quoted here as per the Cambridge News article?):[link] in-situ test for residual protein on reprocessed instruments Hospital Matters 23rd January 2018Delegates visiting Peskett Solutions’ stand at IDSc were keen to learn about ProReveal, currently the only protein detection test that is fully compliant with the requirements of the updated HTM01-01.“This year we devoted our stand to the ProReveal protein detection system,” explains Matthew Peskett, pictured right. “The quick, sensitive, in-situ test to detect residual proteins using fluorescence makes it easy to check the cleanliness of reprocessed instruments. Ten NHS trusts are already benefiting from the adoption of the system.”For further information or to arrange a demonstration, call Peskett Solutions on 01323 511038"
gretel
06 Feb 2018
Director share buying Bouncing nicely.Good to see the non-exec buying shares yesterday at 31.46p. And also reassuring to see him today being issued options only exercisable at 33p. For them to be materially profitable after tax the share price will have to be 50p+ for starters, and hopefully a lot more:[link]
claude reins
02 Feb 2018
Re: not invested yet but,,, What it is to have crystal balls! I wish mine were golden!
Nige the snake
02 Feb 2018
not invested yet but,,, can see the sp going ballistic with a few good RNS reports over 18% increase in a week, I see a 4-5 bagger this year
